Patents Assigned to Welgene Pharmaceuticals, Inc.
  • Patent number: 7420050
    Abstract: The present application describes a purified covalently closed antisense molecule, which specifically inhibits expression of TGF-?.
    Type: Grant
    Filed: December 30, 2002
    Date of Patent: September 2, 2008
    Assignee: Welgene Pharmaceuticals, Inc.
    Inventors: Jong-Gu Park, Ik-Jae Moon, Young-Kook Choi, Kwankyu Park
  • Publication number: 20030165892
    Abstract: The present invention provides a high throughput system for functional genomics using a unigene antisense library comprising LC-antisense compounds. The antisense compounds were specific and effective for the elimination of target mRNA. Thus, the system of the present invention is used as temporary knock-down system to unveil functions of genes critical for diseases. The system of the present invention can be adopted not only for functional genomics but also for effectively validating target for antisense or other molecular therapeutics against various malignancies, infections, and other diseases by blocking specific genes involved in the disease.
    Type: Application
    Filed: May 15, 2002
    Publication date: September 4, 2003
    Applicant: WELGENE PHARMACEUTICALS, INC.
    Inventors: Jong-Gu Park, Ik-Jae Moon, Yun-Han Lee